Categories
Change Password!
Reset Password!
Dual therapy with rabeprazole or vonoprazan achieves similar H. pylori eradication rates as quadruple therapy, while offering better symptom relief, lower inflammation, and good treatment compliance.
A retrospective study analyzing data from 300 Helicobacter pylori (H. pylori)-positive patients suggests that dual therapy regimens using rabeprazole or vonoprazan combined with amoxicillin are just as effective as conventional quadruple therapy in eradicating infection—while offering better symptom control, fewer inflammatory responses, and improved cost-effectiveness.
The study grouped patients into three treatment arms:
Researchers evaluated multiple outcomes, including eradication rates, symptom relief at 14 and 44 days, inflammatory markers (interleukin-6 [IL-6], tumor necrosis factor-alpha[TNF-α], C-reactive protein [CRP]), adverse reactions, compliance, and cost-effectiveness ratios.
Key findings:
Rabeprazole- and vonoprazan-based dual therapies are effective, safe, and well-tolerated alternatives to traditional quadruple therapy for H. pylori infection. They offer added benefits of faster symptom relief and reduced inflammation—with rabeprazole showing an edge in cost-efficiency. These findings support the usage of simplified dual therapy as a practical and patient-friendly treatment option in clinical settings.
American Journal of Translational Research
Rabeprazole- and vonoprazan-based dual therapies for H. pylori eradication: effective with low side effects, rabeprazole being more cost-effective
Xiaoran Sun et al.
Comments (0)